Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing demand for mental health solutions in the region [1][4]. Group 1: Partnership Details - The collaboration will focus on establishing a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - The partnership includes applying for national innovation pilot projects, with Silk Road leading the engagement with Malaysian authorities [3]. - Clinical pilot projects will be initiated in selected hospitals, with the company responsible for local adaptation, training, and data collection [3]. Group 2: Market Context - Malaysia faces challenges with an aging population and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a counselor-to-population ratio of 1:52,000, far below the international standard of 1:500 [1]. Group 3: Strategic Importance - This partnership marks the company's official entry into the Malaysian market, expanding its Southeast Asian business network and leveraging its experience in the Chinese market [4]. - Silk Road's extensive local resources and networks will facilitate efficient product entry and market adaptation, enhancing commercial conversion rates [4]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and accelerate the deployment of its products in local medical institutions [4].

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology to localize and promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, aiming to advance the digital health industry in the region [1][2]. Group 1: Market Context - Malaysia is facing challenges due to rapid population aging and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a psychological counseling ratio of 1:52,000, far below the international standard of 1:500, indicating a substantial market gap [1]. Group 2: Company Background - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first regulatory-approved digital therapy for cognitive impairment, included in the reimbursement catalog of provincial medical insurance in 30 provinces in China [1]. Group 3: Partnership Details - The partnership includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road Technology assisting in local approvals and logistics while the company provides technical and research support [3]. - The collaboration will also involve applying for national innovation pilot projects, conducting clinical trials in selected hospitals, and jointly expanding market reach in Malaysia and other Southeast Asian countries like Indonesia, Thailand, and Vietnam [3]. Group 4: Strategic Benefits - This collaboration is expected to create long-term growth opportunities for the company and sustainable value for shareholders by expanding its international presence and leveraging local resources for efficient market entry [4]. - The partnership enhances the company's brand authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions and broadening its market in digital health management [4].

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote the localization and market development of cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing mental health needs in the region [1][4]. Group 1: Partnership Details - The collaboration includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - Silk Road will lead the application for national innovation pilot projects, facilitating the company's engagement with Malaysian authorities [3]. - The partnership will also focus on clinical pilot projects in hospitals, with Silk Road identifying target hospitals and the company adapting products for local use [3]. - Both parties will work together to expand market presence in Malaysia and other Southeast Asian countries, including Indonesia, Thailand, and Vietnam [3]. Group 2: Market Context and Opportunities - Malaysia is facing challenges related to an aging population and increasing mental health demands, with 3.8 million people aged over 60 in 2023 and a significant shortage of mental health resources [1]. - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first approved digital therapy for cognitive impairment, already included in the reimbursement catalog of 30 provinces in China [1]. - The partnership is expected to enhance the company's international presence and brand influence, leveraging Silk Road's extensive local resources and networks in Malaysia to accelerate market entry and improve commercial conversion efficiency [4].

BrainAurora Medical Technology Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6681） 自願公告 訂立戰略合作協議以拓展馬來西亞市場及深化國際化布局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發布的公告，目的是使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣布，本公司與絲路之舟科技有限公司（「絲路之 舟」）訂立戰略合作協議（「協議」），雙方將在馬來西亞及東南亞區域圍繞認知障礙 數字療法產品的本土化落地、市場推廣與科研轉化等領域開展深度戰略合作，共 同推動數字健康產業發展。 合作背景與內容 馬來西亞為東南亞重要經濟體之一，正面臨快速人口老化及精神健康需求攀升 的挑戰。根據馬來西亞統計局數據，2023年該國60歲以上人口達380萬。與此同 時，青少年心理健康問題亦日益突出。馬來西亞政府雖已推動多項精神健康政 策，然診療資源仍顯稀 ...

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources for targeted recommendations and full-service support [2]. - Market expansion efforts will involve integrating resources such as products, channels, brands, and technology to penetrate Singapore's healthcare system, focusing on private and public hospitals [2]. Group 2: Long-term Development Opportunities - This partnership is expected to enhance the company's international presence and expand into Southeast Asia, building on previous experiences in Hong Kong and Macau [3]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and expedite product integration into local medical institutions, thereby broadening its market reach [3].

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote and expand its digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources to recommend the products to target users and provide full-service support [2]. - Market expansion collaboration will involve integrating resources such as products, channels, brands, and technology to jointly develop the Singapore market, focusing on introducing the company's products into leading private and public hospitals [2]. Group 2: Long-term Development Opportunities - The cooperation is expected to deepen the company's international presence and expand into overseas markets, marking the official launch of its Southeast Asia market strategy, building on prior experiences in Hong Kong and Macau [3]. - This partnership is anticipated to enhance the company's brand influence and commercial network in the digital healthcare sector, facilitating quicker product integration into local medical institutions and diversifying into various digital health management markets [3].

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion in Singapore, leveraging the local government's initiatives for early screening and health management for cognitive disorders [1]. - The company will localize its cognitive disorder digital therapy products for the Singapore market, while Natural Health Solutions will utilize its network to recommend these products to target users [2]. Group 2: Market Expansion - The collaboration aims to integrate resources such as products, channels, and technology to penetrate the Singapore healthcare system, particularly targeting private and public hospitals [2]. - This partnership marks the company's formal entry into the Southeast Asian market, building on its previous experiences in Hong Kong and Macau [3]. Group 3: Long-term Opportunities - The cooperation is expected to enhance the company's international presence and brand influence, allowing it to export its digital therapy expertise to other supportive regions [3]. - The partnership will strengthen the company's authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 訂立戰略合作協議以拓展新加坡市場及推動國際化佈局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者瞭解本集團最新業務發展情況。 根據協議，雙方合作主要包括以下內容：(I)產品推廣合作：本公司負責認知障礙 數字療法產品在新加坡的本土化適配、系統落地及人員培訓支持；萊賀思寶將依 託其全部線下門店及會員資源，向目標用戶定向推薦本公司產品，並負責全流程 服務，包括產品介紹、試用引導、購買轉化及售後支持。(II)市場拓展協同：雙方 整合產品、渠道、品牌與技術等資源，共同開拓新加坡市場，重點推動本公司產 品進入新加坡頭部私立醫院及公立醫院體系，提升產品在當地醫療系統中的應用 與普及。 ...

Core Insights - The stock of Brain Dynamics Aurora-B (06681) surged over 14%, reaching HKD 8.5 with a trading volume of HKD 311 million [1] Industry Developments - The Minister of Industry and Information Technology, Li Lecheng, emphasized the need to cultivate emerging industries and create new momentum during the 25th China International Industry Fair, focusing on technological innovation and the establishment of new pillar industries [1] - The National Medical Products Administration has approved the first medical device standard for brain-computer interface technology, which will be implemented on January 1, 2026, laying the foundation for the high-quality development of the brain-computer interface medical device industry [1] Company Highlights - Brain Dynamics Aurora's core product is a brain function information management platform software system, recognized as China's first regulatory-approved digital therapy product for cognitive impairment [2] - The company combines brain science with artificial intelligence, offering unique technological advantages such as virtual human technology and AI [2] - As the first company in China to develop a medical-grade digital therapy product for cognitive impairment, Brain Dynamics Aurora holds a first-mover advantage [2] - The core product is included in the provincial medical insurance reimbursement catalog across 30 provinces in China, enhancing product accessibility and market promotion [2] - The company has successfully established cognitive centers in over 120 hospitals in China, including several leading hospitals certified as "National Medical Centers" [2]

Core Viewpoint - Tencent's cognitive training software "Tencent Brain Exercise" has received medical device registration approval from the Guangdong Provincial Drug Administration, marking its entry into clinical application for improving cognitive abilities in patients with mild cognitive impairment (MCI) [1][3] Industry Overview - The cognitive digital therapy market in China has over 40 companies focusing on this area, with 47 cognitive digital therapy software products approved by the National Medical Products Administration as of October 2024 [2] - The market for cognitive impairment digital therapy is expected to grow significantly, with a projected market size of 2.686 billion yuan in 2023, increasing to 10.467 billion yuan by 2025 and 89.274 billion yuan by 2030, reflecting compound annual growth rates of 97.4% and 53.5% respectively [4] - The number of MCI patients in China is approximately 38.77 million, with a prevalence rate of 15.5%, indicating a substantial patient base driving demand for cognitive digital therapies [4] Company Insights - Tencent's "Tencent Brain Exercise" transforms traditional cognitive rehabilitation into a mobile application format, utilizing gamified cognitive training based on evidence-based medicine principles [3] - The company aims to address the challenges of commercializing digital therapies, as the current business models are still in the early stages of development [1][2] - Brain Dynamics, a competitor in the market, has achieved a market share of 25.0% in the cognitive digital therapy market and 91.6% in the medical-grade cognitive digital therapy market in China, but faces challenges in profitability despite significant revenue growth [5] Challenges in the Market - The cognitive digital therapy sector is experiencing high market education costs and is still in the exploratory phase regarding application scenarios [1][2] - Regulatory challenges exist, as clinical experts have varying opinions on the clinical use of digital therapy products, which complicates their appropriate application [4][5] - The industry faces difficulties in ensuring that payers (such as insurance companies and hospitals) are willing to cover these therapies, which is crucial for sustainable business models [1][2] Competitive Landscape - Major tech companies like Tencent, Alibaba, and ByteDance are entering the healthcare sector, but a mature commercialization model is still needed [6] - The cognitive digital therapy market is characterized by a mix of substantial patient demand and ongoing challenges in commercialization pathways, creating a complex development landscape [2][4]